Form 4: Checkpoint Therapeutics Director Disposes of All Shares Following Merger Agreement

Christian Bechon, a Director at Checkpoint Therapeutics, Inc., has disposed of all his common stock holdings in connection with the previously announced merger agreement, receiving cash and contingent value rights.

Summary

• Christian Bechon, a Director of Checkpoint Therapeutics, Inc. (CKPT), disposed of all 141,718 shares of common stock he beneficially owned.
• The disposition occurred on May 30, 2025, as part of an offer made pursuant to the Agreement and Plan of Merger, dated March 9, 2025, and amended April 14, 2025.
• Prior to this, on May 28, 2025, Mr. Bechon acquired 12,195 shares of common stock at a price of $0.00, likely related to vesting of restricted stock.
• For each share, Mr. Bechon received $4.10 in cash, net to the holder, plus one contractual contingent value right (CVR).
• Each CVR entitles the holder to a payment ranging from $0.20 to $0.70, contingent on specific milestone payments related to the regulatory approval of cosibelimab in the European Union.
• The CVR milestone must be achieved within 36 months after cosibelimab's marketing authorization application receives a positive validation outcome by the European Medicines Agency.
• Following these transactions, Mr. Bechon holds 0 shares of Checkpoint Therapeutics common stock.

Sentiment

Score: 7

Explanation: The transaction represents the completion of a merger, providing liquidity to shareholders and potential upside via CVRs, which is generally positive for shareholders. The director's complete divestment is a natural outcome of the merger.

Positives

• The disposition of shares is part of a merger agreement, indicating a successful acquisition for shareholders.
• Shareholders received a cash payment of $4.10 per share.
• The inclusion of a Contingent Value Right (CVR) provides potential additional upside of $0.20 to $0.70 per share based on future regulatory milestones for cosibelimab in the EU.

Negatives

• The director no longer holds any common stock in Checkpoint Therapeutics, Inc.

Risks

• The Contingent Value Right (CVR) payment is not guaranteed and is dependent on the achievement of specific regulatory milestones for cosibelimab in the European Union.
• The CVR milestone must be achieved within a 36-month timeframe after a positive validation outcome by the European Medicines Agency, introducing a time-bound risk.
• The actual payment from the CVR can range from $0.20 to $0.70, meaning the full potential value may not be realized.

Future Outlook

The future outlook for Checkpoint Therapeutics shareholders who received CVRs is tied to the regulatory approval of cosibelimab in the European Union. A positive validation outcome by the European Medicines Agency and subsequent achievement of defined milestones within 36 months could lead to additional payments ranging from $0.20 to $0.70 per CVR.

Industry Context

This filing reflects the final stages of a merger transaction in the biotechnology/pharmaceutical sector, a common strategy for smaller companies with promising drug candidates (like cosibelimab) to be acquired by larger entities, providing liquidity to shareholders and potentially accelerating drug development and commercialization through the acquirer's resources. The use of Contingent Value Rights (CVRs) is a growing trend in biotech M&A, allowing acquirers to mitigate risk while providing sellers with upside potential tied to clinical or regulatory success.

Stakeholder Impact

• Shareholders: Received cash consideration of $4.10 per share and Contingent Value Rights (CVRs) offering potential additional payments based on future regulatory milestones, providing liquidity and potential upside from the merger.
• Director (Christian Bechon): Has fully divested his common stock holdings in Checkpoint Therapeutics, aligning with the completion of the merger.

Next Steps

• Monitoring the progress of cosibelimab's marketing authorization application with the European Medicines Agency.
• Awaiting potential payments from the Contingent Value Rights (CVRs) if regulatory milestones for cosibelimab in the EU are achieved within the specified 36-month timeframe.

Key Dates

Keywords

Checkpoint Therapeutics, CKPT, SEC Form 4, Director Share Disposition, Merger Agreement, Contingent Value Right, CVR, Cosibelimab, European Union Regulatory Approval, Biotechnology, Pharmaceuticals, Shareholder Value